Previous 10 | Next 10 |
2023-11-07 20:07:02 ET MannKind Corporation (MNKD) Q3 2023 Earnings Conference Call November 07, 2023, 5:00 PM ET Company Participants Michael Castagna - Chief Executive Officer Steven Binder - Chief Financial Officer Conference Call Participants Gregory ...
2023-11-07 16:01:40 ET More on MannKind MannKind: Are They Working With A Friend Or A Foe? Tyvaso DPI Is Breathing New Life Into MannKind's Balance Sheet (Rating Upgrade) MannKind Q3 2023 Earnings Preview Earnings week ahead: Disney, AMC, Plug Power, Lucid, R...
Conference Call to Begin Today at 5:00 p.m. (ET) 3Q 2023 Total revenues of $51M; +56% vs. 3Q 2022 3Q YTD 2023 Total revenues of $140M; +121% vs. 3Q YTD 2022 3Q 2023 Net income of $2M; Non-GAAP net income of $4M 3Q 2023 Tyvaso DPI royalties of $20M; +225% vs. 3Q...
Weyco Group Inc. (WEYS) is expected to report for Q1 2024 Gladstone Land Corporation (LAND) is expected to report $0.16 for Q3 2023 PlayAGS Inc. (AGS) is expected to report $0.01 for Q3 2023 Ardmore Shipping Corporation (ASC) is expected to report $0.43 for Q3 2023 Sage Therapeuti...
MannKind Corporation (MNKD) is expected to report $-0.02 for Q3 2023
2023-11-05 23:46:57 ET In the upcoming week of November, investors can anticipate a flurry of quarterly reports from major companies, promising significant market activity. Notable among them is Disney ( NYSE: DIS ), a household name set to disclose its financial performance. ...
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Oct. 31, 2023 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) will release its 2023 third quarter financial results and year to date financial results and its management will host a conference call to discuss these results and corporate upd...
2023-10-31 02:17:12 ET Summary I will recap the eleven partnership deals MannKind has been involved in over its operation as a corporation. I will share my opinion as it relates to the current status of these eleven partnerships. I will discuss why it is my opinion that MannKi...
Patent covers compositions of clofazimine, and methods for treating lung infections Development of MNKD-101 (inhaled clofazimine) continues for the potential treatment of nontuberculous mycobacterial (NTM) lung disease DANBURY, Conn., Oct. 30, 2023 (GLOBE NEWSWIRE) -- MannKind C...
2023-10-18 00:04:36 ET Summary Tyvaso DPI, a collaboration with United Therapeutics, diversifies MannKind's revenue streams and leverages its proprietary Technosphere technology, bolstering long-term prospects. While Afrezza faces challenges like pricing and reimbursement, MNKD's ...
News, Short Squeeze, Breakout and More Instantly...
2024-07-27 10:08:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Study proves inhaled insulin is as effective as usual care (primarily automated insulin delivery pumps or multiple daily injections) for adults living with T1D meeting the primary endpoint Patients utilizing inhaled insulin reached target A1c (less than 7%) 30% of the time compared to 17%...
17-week endpoint results comparing Afrezza ® head-to-head with multiple daily injections (MDI) and insulin pumps INHALE-3 Study Protocol Chair Dr. Irl. B. Hirsh joined by investigational team to deliver presentation moderated by Jaeb Center founder Dr. Roy W. Beck ...